Publication date: Jul 01, 2025
mRNA vaccines have shown great efficacy against SARS-CoV-2, yet challenges remain in optimizing vaccine components to achieve enhanced immune response and vaccine stability. In this study, we developed CPVax-CoV, a new lyophilized mRNA vaccine that features novel thiolactone-based ionizable lipids and newly designed untranslated regions (UTRs) for enhanced expression. Incorporation of these optimized components into our vaccine candidate CPVax-CoV significantly improved immune responses in mice compared to commercially available mRNA vaccines. Moreover, lyophilized CPVax-CoV has proven to be thermostable, maintaining its biological activity for up to one year at 4 ^0C and 25 ^0C after lyophilization, overcoming the cold-chain limitations of current mRNA vaccines. This vaccine demonstrates protective efficacy against ancestral SARS-CoV-2 and the Omicron XBB variant, offering a scalable solution for global distribution and pandemic preparedness. These findings underscore the potential of this platform for future next-generation mRNA vaccine development.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Lipids | 25c |
| Mrna | Cov |
| Pandemic | Cpvax |
| Proven | Efficacy |
| Vaccine | Enhanced |
| Immune | |
| Ionizable | |
| Lipids | |
| Lyophilized | |
| Mrna | |
| Preserved | |
| Sars | |
| Vaccine | |
| Vaccines | |
| Year |